Floatz logo

Bisoprolol Fumarate

Abdominal Obesity-Metabolic Syndrome

Ukrainian Medical Stomatological AcademyUNKNOWNPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

42 Active assets in the Abdominal Obesity-Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Atorvastatin
Seoul National University Hospital
Phase 4BBB
Topiramate
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB
Olmesartan Medoxomil
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB

View all 50 →

Same molecule, other indications

Bisoprolol Fumarate is also rated in:

coronary atherosclerosisDormant
BB
Indicative · Phase 4
69 / 100
View asset →
iatrogenicDormant
BB
Indicative · Phase 4
69 / 100
View asset →
dilated cardiomyopathyDormant
B
Indicative · Phase 2/3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →